Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT
POSSIBLE COOPERATION FOR LOCALISATION IN THE PRC

This announcement is made by Sisram Medical Ltd (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Company is pleased to announce a strategic cooperation framework established through a memorandum of understanding (the "**MOU**") entered into in January 2026 between the Company and Sinmait Medical Technology (Beijing) Co., Ltd.* (星邁泰科醫療科技(北京)有限公司) ("**Sinmait Medical**"), in relation to a possible cooperation (the "**Possible Cooperation**") for localisation in the People's Republic of China (the "**PRC**").

Pursuant to the MOU, the Possible Cooperation focuses on initiating a local manufacturing presence for the Group's energy-based medical devices in the PRC, one of the Group's core strategic markets. This marks an important step in the Company's strategy to deepen its customer-centric approach by effectively shortening supply chain and enhancing local agility. Besides catering domestic demand, this move creates a regional cornerstone for Asia-Pacific strategic hub to fulfil the growing needs for scaled production, sophisticated logistics, and advanced technology across the entire region.

As Sinmait Medical is an indirect wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (Stock Codes: 2196.HK and 600196.SH), which is a controlling shareholder of the Company, Sinmait Medical is a connected person of the Company by virtue of being an associate of the Company's connected person. Accordingly, in the event that the Possible Cooperation materialises, it might constitute notifiable and/or connected transaction(s) of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The MOU is not legally binding. If the Possible Cooperation materialises, further announcement(s) in relation to the Possible Cooperation will be made by the Company as and when appropriate in compliance with the Listing Rules.

As the Possible Cooperation is subject to whether any definitive agreement(s) will be entered into and may or may not proceed, shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Sisram Medical Ltd
復鋭醫療科技有限公司*
Lior Moshe DAYAN
Chairman

Hong Kong, 21 January, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purpose only*